AIM: Fatty acid-CoA ligase 4 (FACL4) is an arachidonate-preferring enzyme which has been shown to be up-regulated in human colon cancer tissues and implicated in the colon tumorigenesis. The purpose of this study was to investigate the role of FACL4 in the human hepatocellular carcinoma (HCC) tumorigenesis and the specific signal pathways involved in this process. METHODS: We investigated the expression and regulation of FACL4 in HCC, adjacent non-tumorous liver tissues, and cell lines. RESULTS: In HCC patients, we demonstrated that FACL4 gene expression was markedly elevated in the cancerous tissues than in the adjacent non-cancerous liver tissues. In addition, several human hepatoma cell lines, including Hep3B and HepG2, expressed high levels of FACL4. Stable overexpression of FACL4 knockdown plasmids (small interfering RNA, siRNA) to Hep3B cells significantly decreased FACL4 expression and subsequently limited the cell proliferation. Treatment of Hep3B cells with 8-bromo-cAMP and SB203508 (p38 MAPK inhibitor) significantly suppressed the FACL4 expression. CONCLUSION: FACL4 is involved in the HCC tumorigenesis and both cAMP and p38 MAPK pathways are associated with the regulation of FACL4 in HCC.
AIM: Fatty acid-CoA ligase 4 (FACL4) is an arachidonate-preferring enzyme which has been shown to be up-regulated in humancolon cancer tissues and implicated in the colon tumorigenesis. The purpose of this study was to investigate the role of FACL4 in the humanhepatocellular carcinoma (HCC) tumorigenesis and the specific signal pathways involved in this process. METHODS: We investigated the expression and regulation of FACL4 in HCC, adjacent non-tumorous liver tissues, and cell lines. RESULTS: In HCC patients, we demonstrated that FACL4 gene expression was markedly elevated in the cancerous tissues than in the adjacent non-cancerous liver tissues. In addition, several humanhepatoma cell lines, including Hep3B and HepG2, expressed high levels of FACL4. Stable overexpression of FACL4 knockdown plasmids (small interfering RNA, siRNA) to Hep3B cells significantly decreased FACL4 expression and subsequently limited the cell proliferation. Treatment of Hep3B cells with 8-bromo-cAMP and SB203508 (p38 MAPK inhibitor) significantly suppressed the FACL4 expression. CONCLUSION:FACL4 is involved in the HCC tumorigenesis and both cAMP and p38 MAPK pathways are associated with the regulation of FACL4 in HCC.
Authors: Y J Bang; F Pirnia; W G Fang; W K Kang; O Sartor; L Whitesell; M J Ha; M Tsokos; M D Sheahan; P Nguyen; W T Niklinski; C E Myers; J B Trepel Journal: Proc Natl Acad Sci U S A Date: 1994-06-07 Impact factor: 11.205
Authors: Marie E Monaco; Chad J Creighton; Peng Lee; Xuanyi Zou; Matthew K Topham; Diana M Stafforini Journal: Transl Oncol Date: 2010-04 Impact factor: 4.243
Authors: Paula M Maloberti; Alejandra B Duarte; Ulises D Orlando; María E Pasqualini; Angela R Solano; Carlos López-Otín; Ernesto J Podestá Journal: PLoS One Date: 2010-11-11 Impact factor: 3.240
Authors: Beyza Bulutoglu; Camilo Rey-Bedón; Young Bok Abraham Kang; Safak Mert; Martin L Yarmush; O Berk Usta Journal: Lab Chip Date: 2019-09-10 Impact factor: 6.799